Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 6 | 2024 | 277 | 1.780 |
Why?
|
| Trypanosoma cruzi | 4 | 2024 | 221 | 1.760 |
Why?
|
| HIV Infections | 5 | 2024 | 2134 | 1.730 |
Why?
|
| Chagas Cardiomyopathy | 5 | 2015 | 45 | 1.360 |
Why?
|
| Emigrants and Immigrants | 2 | 2020 | 147 | 1.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 651 | 0.950 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 715 | 0.940 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 761 | 0.940 |
Why?
|
| Laryngostenosis | 1 | 2023 | 37 | 0.920 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 980 | 0.860 |
Why?
|
| Pandemics | 3 | 2020 | 1559 | 0.800 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2021 | 36 | 0.790 |
Why?
|
| Strongyloides stercoralis | 1 | 2020 | 22 | 0.770 |
Why?
|
| Strongyloidiasis | 1 | 2020 | 24 | 0.770 |
Why?
|
| Contact Tracing | 1 | 2021 | 56 | 0.760 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 102 | 0.760 |
Why?
|
| Betacoronavirus | 3 | 2020 | 527 | 0.760 |
Why?
|
| Helminthiasis | 1 | 2021 | 67 | 0.750 |
Why?
|
| Health Communication | 1 | 2020 | 37 | 0.750 |
Why?
|
| Veterans | 2 | 2022 | 1641 | 0.730 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 175 | 0.710 |
Why?
|
| Viremia | 1 | 2020 | 177 | 0.710 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 171 | 0.690 |
Why?
|
| Immune Tolerance | 1 | 2021 | 403 | 0.680 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 167 | 0.660 |
Why?
|
| Organ Transplantation | 1 | 2020 | 191 | 0.640 |
Why?
|
| Merozoite Surface Protein 1 | 3 | 2012 | 11 | 0.600 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 335 | 0.600 |
Why?
|
| HIV | 3 | 2024 | 229 | 0.590 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 1146 | 0.590 |
Why?
|
| Malaria, Falciparum | 3 | 2012 | 46 | 0.580 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 350 | 0.580 |
Why?
|
| Plasmodium falciparum | 3 | 2012 | 65 | 0.570 |
Why?
|
| Vaccination | 1 | 2020 | 1123 | 0.490 |
Why?
|
| Immunologic Memory | 2 | 2012 | 374 | 0.440 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 213 | 0.400 |
Why?
|
| Antibodies, Protozoan | 4 | 2014 | 87 | 0.390 |
Why?
|
| United States | 7 | 2024 | 15433 | 0.380 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 1833 | 0.370 |
Why?
|
| Bolivia | 7 | 2017 | 21 | 0.320 |
Why?
|
| Papillomaviridae | 2 | 2021 | 624 | 0.310 |
Why?
|
| Humans | 32 | 2024 | 261506 | 0.280 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 1021 | 0.270 |
Why?
|
| Rituximab | 2 | 2021 | 1528 | 0.260 |
Why?
|
| Insecticides | 2 | 2017 | 49 | 0.260 |
Why?
|
| Biomarkers | 3 | 2015 | 5047 | 0.250 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 4314 | 0.240 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 15 | 0.220 |
Why?
|
| Helminths | 1 | 2022 | 37 | 0.210 |
Why?
|
| Female | 18 | 2022 | 141928 | 0.200 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 239 | 0.200 |
Why?
|
| Kava | 1 | 2020 | 9 | 0.190 |
Why?
|
| Antigens, Protozoan | 2 | 2012 | 66 | 0.190 |
Why?
|
| Unemployment | 1 | 2020 | 31 | 0.190 |
Why?
|
| Malaria Vaccines | 2 | 2012 | 20 | 0.190 |
Why?
|
| Data Accuracy | 1 | 2020 | 54 | 0.190 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 101 | 0.180 |
Why?
|
| Housing | 1 | 2020 | 61 | 0.180 |
Why?
|
| Leadership | 1 | 2022 | 254 | 0.180 |
Why?
|
| Early Diagnosis | 1 | 2021 | 298 | 0.180 |
Why?
|
| Food Supply | 1 | 2020 | 97 | 0.180 |
Why?
|
| Eosinophils | 1 | 2020 | 162 | 0.180 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 76 | 0.180 |
Why?
|
| Peru | 4 | 2012 | 52 | 0.170 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 264 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 182 | 0.170 |
Why?
|
| Developing Countries | 1 | 2021 | 315 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 173 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 203 | 0.170 |
Why?
|
| Bone Density | 1 | 2022 | 476 | 0.170 |
Why?
|
| Public Health | 1 | 2021 | 299 | 0.160 |
Why?
|
| Fatal Outcome | 1 | 2020 | 829 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 242 | 0.160 |
Why?
|
| Adult | 15 | 2022 | 77950 | 0.160 |
Why?
|
| Syndrome | 1 | 2021 | 1351 | 0.160 |
Why?
|
| Endemic Diseases | 2 | 2015 | 67 | 0.150 |
Why?
|
| Health Policy | 1 | 2020 | 291 | 0.150 |
Why?
|
| Pyrethrins | 1 | 2017 | 8 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2021 | 649 | 0.150 |
Why?
|
| Insecticide Resistance | 1 | 2017 | 28 | 0.150 |
Why?
|
| Triatoma | 1 | 2017 | 28 | 0.140 |
Why?
|
| Poverty | 1 | 2020 | 471 | 0.140 |
Why?
|
| Insect Proteins | 1 | 2017 | 91 | 0.140 |
Why?
|
| Risk Factors | 4 | 2022 | 17523 | 0.140 |
Why?
|
| Young Adult | 8 | 2022 | 21445 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1225 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1586 | 0.140 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2015 | 29 | 0.140 |
Why?
|
| Ventricular Premature Complexes | 1 | 2015 | 16 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2015 | 343 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 1489 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2315 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 1294 | 0.130 |
Why?
|
| Middle Aged | 12 | 2022 | 86204 | 0.130 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 36 | 0.130 |
Why?
|
| Bundle-Branch Block | 1 | 2015 | 43 | 0.130 |
Why?
|
| Adolescent | 9 | 2022 | 31252 | 0.130 |
Why?
|
| Neoplasms | 1 | 2021 | 15193 | 0.130 |
Why?
|
| Chromatography, Affinity | 1 | 2014 | 122 | 0.130 |
Why?
|
| Electrocardiography | 3 | 2015 | 1145 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 256 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 598 | 0.120 |
Why?
|
| Male | 13 | 2022 | 123000 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2022 | 37905 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2021 | 3005 | 0.120 |
Why?
|
| Insect Control | 1 | 2013 | 13 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2021 | 1230 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2020 | 925 | 0.110 |
Why?
|
| Stroke Volume | 1 | 2015 | 577 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2015 | 1271 | 0.110 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 34 | 0.110 |
Why?
|
| Nitriles | 1 | 2017 | 906 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1582 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 4744 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 435 | 0.100 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 141 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 2012 | 114 | 0.100 |
Why?
|
| Child, Preschool | 7 | 2020 | 16273 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 1904 | 0.090 |
Why?
|
| Incidence | 1 | 2020 | 5673 | 0.090 |
Why?
|
| Child | 9 | 2020 | 29154 | 0.090 |
Why?
|
| Global Health | 1 | 2014 | 657 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 29902 | 0.080 |
Why?
|
| Antigens, CD19 | 1 | 2012 | 577 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 610 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2014 | 806 | 0.070 |
Why?
|
| Aged | 8 | 2022 | 70117 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2015 | 19 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2015 | 66 | 0.060 |
Why?
|
| Prevalence | 3 | 2022 | 3260 | 0.060 |
Why?
|
| Rural Population | 2 | 2017 | 281 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 360 | 0.060 |
Why?
|
| Animals | 5 | 2022 | 59536 | 0.060 |
Why?
|
| Obesity | 1 | 2015 | 2884 | 0.050 |
Why?
|
| Blood Donors | 1 | 2022 | 164 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 2 | 2013 | 129 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 397 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2819 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2022 | 498 | 0.040 |
Why?
|
| Infant | 4 | 2020 | 13310 | 0.040 |
Why?
|
| Nymph | 1 | 2017 | 10 | 0.040 |
Why?
|
| Esterases | 1 | 2017 | 19 | 0.040 |
Why?
|
| Voltage-Gated Sodium Channels | 1 | 2017 | 12 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 1217 | 0.040 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 32 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 200 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 106 | 0.030 |
Why?
|
| Troponin I | 1 | 2015 | 127 | 0.030 |
Why?
|
| Serum | 1 | 2014 | 68 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 292 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 3639 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8223 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 484 | 0.030 |
Why?
|
| Mali | 1 | 2011 | 10 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 390 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6009 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 5687 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1182 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 486 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 2203 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2011 | 1385 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 3033 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 2437 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 9244 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 4758 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 4109 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7573 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 14889 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 21713 | 0.010 |
Why?
|